Guerbet S. A.
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more
Market Cap & Net Worth: Guerbet S. A. (GBT)
Guerbet S. A. (PA:GBT) has a market capitalization of $106.18 Million (€103.44 Million) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #21811 globally and #174 in its home market, demonstrating a -33.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guerbet S. A.'s stock price €8.20 by its total outstanding shares 12615123 (12.62 Million).
Guerbet S. A. Market Cap History: 2015 to 2026
Guerbet S. A.'s market capitalization history from 2015 to 2026. Data shows change from $701.71 Million to $106.18 Million (-15.69% CAGR).
Index Memberships
Guerbet S. A. is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$47.81 Billion | 0.09% | #54 of 119 |
|
CAC Small90
CACS
|
$12.04 Billion | 0.37% | #30 of 64 |
|
CAC All-Tradable
CACT
|
$485.02 Billion | 0.01% | #68 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$485.02 Billion | 0.01% | #68 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$485.02 Billion | 0.01% | #68 of 179 |
|
CAC Health Care
FRHC
|
$71.02 Billion | 0.06% | #13 of 36 |
Weight: Guerbet S. A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Guerbet S. A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guerbet S. A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
Guerbet S. A.'s market cap is 0.41 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
21.58x
Guerbet S. A.'s market cap is 21.58 times its annual earnings
1.97x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $701.71 Million | $489.91 Million | $39.92 Million | 1.43x | 17.58x |
| 2016 | $779.37 Million | $776.47 Million | $28.93 Million | 1.00x | 26.94x |
| 2017 | $877.24 Million | $808.63 Million | $46.22 Million | 1.08x | 18.98x |
| 2018 | $588.62 Million | $794.61 Million | $46.82 Million | 0.74x | 12.57x |
| 2019 | $471.95 Million | $816.91 Million | $37.33 Million | 0.58x | 12.64x |
| 2020 | $383.01 Million | $712.29 Million | $18.24 Million | 0.54x | 21.00x |
| 2021 | $444.81 Million | $735.91 Million | $32.64 Million | 0.60x | 13.63x |
| 2022 | $210.28 Million | $769.50 Million | -$41.12 Million | 0.27x | N/A |
| 2023 | $248.92 Million | $795.65 Million | $23.87 Million | 0.31x | 10.43x |
| 2024 | $347.04 Million | $851.12 Million | $16.08 Million | 0.41x | 21.58x |
Competitor Companies of GBT by Market Capitalization
Companies near Guerbet S. A. in the global market cap rankings as of March 18, 2026.
Key companies related to Guerbet S. A. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
Guerbet S. A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Guerbet S. A.'s market cap moved from $701.71 Million to $ 106.18 Million, with a yearly change of -15.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €106.18 Million | -42.66% |
| 2025 | €185.17 Million | -46.64% |
| 2024 | €347.04 Million | +39.42% |
| 2023 | €248.92 Million | +18.37% |
| 2022 | €210.28 Million | -52.72% |
| 2021 | €444.81 Million | +16.14% |
| 2020 | €383.01 Million | -18.85% |
| 2019 | €471.95 Million | -19.82% |
| 2018 | €588.62 Million | -32.90% |
| 2017 | €877.24 Million | +12.56% |
| 2016 | €779.37 Million | +11.07% |
| 2015 | €701.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Guerbet S. A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $106.18 Million USD |
| MoneyControl | $106.18 Million USD |
| MarketWatch | $106.18 Million USD |
| marketcap.company | $106.18 Million USD |
| Reuters | $106.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.